QuidelOrtho Corp. 10-Q Summary: Fiscal Q2 2026
Business Context and Reporting Period
This filing covers the quarterly period ended June 28, 2026. QuidelOrtho Corporation operates globally across five reportable segments: North America, EMEA, China, JPAC, and Latin America. The company focuses on immunoassay, molecular testing, clinical chemistry, and transfusion medicine. Key strategic developments in this period include the acquisition of LEX Diagnostics to expand point-of-care molecular capabilities and the continued wind-down of the U.S. donor screening portfolio.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $630.9 million | $613.9 million | $1,250.7 million | $1,306.7 million |
| Net Loss | $(92.9) million | $(255.4) million | $(184.7) million | $(268.1) million |
| Operating Loss | $(21.8) million | $(180.7) million | $(53.6) million | $(148.1) million |
| Adjusted EBITDA (Total Segments) | $260.0 million | $258.0 million | $502.3 million | $567.7 million |
| Cash and Equivalents | $123.4 million | $169.8 million (Dec 2025) | $123.4 million | $151.7 million (Jun 2025) |
| Total Debt (Current + Long-term) | $2,891.1 million | $2,650.2 million (Dec 2025) | $2,891.1 million | $2,650.2 million (Dec 2025) |
| Operating Cash Flow | Not provided for Q2 | Not provided for Q2 | $(143.6) million | $18.8 million |
Material Changes vs. Prior Period
- Revenue Trends: Q2 2026 revenue increased 3% year-over-year, driven by growth in Labs (+4%) and Point of Care (+16%) segments. However, YTD revenue declined 4% due to the termination of the Joint Business with Grifols and lower respiratory product demand.
- Profitability Improvement: Net loss narrowed significantly to $92.9 million in Q2 2026 compared to $255.4 million in Q2 2025. This improvement is largely attributable to the absence of the $178.9 million in restructuring charges recorded in the prior year related to the SAVANNA Exit and combination integration.
- Restructuring Charges: Current period restructuring charges were minimal ($6.5 million in Q2) compared to $178.9 million in the prior year. The company is executing an "Optimization Plan" with cumulative expected charges of $100 million through 2027.
- Acquisition: The company acquired LEX Diagnostics in April 2026 for $174.6 million, adding the LEX VELO System technology.
- Debt Levels: Total borrowings increased to $2.89 billion, reflecting new borrowings to fund the LEX acquisition and working capital needs.
Guidance, Outlook, and Risks
- Outlook: Management expects respiratory product demand to remain volatile and potentially weak through the second half of 2026. Pricing pressures in China due to evolving IVD guidelines are expected to persist.
- Strategic Initiatives: The company is focused on the "Optimization Plan" to achieve $50 million in net cost savings by 2027 and the integration of LEX Diagnostics to accelerate point-of-care growth.
- Risks:
- Trade and Tariffs: New U.S. tariffs and global trade tensions are increasing costs for parts, materials, and shipping. While the company has offset some costs, future impacts remain uncertain.
- China Market: Uncertainty regarding the China National Health Security Administration (NHSA) pricing guidelines has led to slower distributor sales.
- Legal Proceedings: The company faces putative class action and derivative lawsuits regarding COVID-19 test sales and the SAVANNA RVP4 assay. The company disputes these allegations but cannot estimate potential losses.
- Liquidity: The company maintains $123.4 million in cash and $426.5 million in availability under its Revolving Credit Facility. Management believes these resources are sufficient for the next 12 months.
Key Facts for Investor Verification
- Respiratory Demand: Verify the severity of the upcoming flu/RSV season and its impact on Q3/Q4 revenue, as respiratory products accounted for 8-9% of revenue in the first half of 2026.
- China Pricing Impact: Monitor the finalization of China's NHSA pricing guidelines and their specific effect on the Labs segment, which saw a 17% YTD revenue decline in that region.
- Debt Service: Review the company's ability to service $2.89 billion in debt with an effective interest rate of ~6.97% while operating with a net loss.
- LEX Integration: Assess the timeline for revenue contribution from the LEX Diagnostics acquisition and the realization of synergies.
- Legal Exposure: Track the status of the Bristol County and derivative lawsuits regarding COVID-19 disclosures and the SAVANNA platform.